ConductScience.org, home

Paper29799080

The challenge of drug resistance in cancer treatment: a current overview.

Nikolaou M and 3 others. Clin Exp Metastasis, 2018. Cited by 415 papers, by iCite.

Cite this record

ConductScience Library. The challenge of drug resistance in cancer treatment: a current overview. Papers, record 29799080. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/29799080

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The challenge of drug resistance in cancer treatment: a current overview.
PubMed
Journal
Clin Exp Metastasis
PubMed
Year
2018
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't, Review
PubMed
Citations, by iCite
415
iCite
Relative citation ratio, by iCite
17.4
iCite
Revised in PubMed
2022-04-09
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Nikolaou MMichail
2Pavlopoulou AAthanasia
3Georgakilas AGAlexandros G
4Kyrodimos EEfthymioshttps://orcid.org/0000-0001-5236-7961

Source PubMed

Download CSV of authors

Topics3

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Drug Resistance, NeoplasmMajor topic
NeoplasmsMajor topic
Humans

References125

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
116518375Targeting multidrug resistance in cancer.Nat Rev Drug Discov2006https://conductscience.org/library/papers/16518375PubMed
27642470Clinical resistance to antimetabolites.Hematol Oncol Clin North Am1995https://conductscience.org/library/papers/7642470PubMed
3421240Tumour cell proliferation in relation to the vasculature.Cell Tissue Kinet1979https://conductscience.org/library/papers/421240PubMed
416636113Evolution of resistance during clonal expansion.Genetics2006https://conductscience.org/library/papers/16636113PubMed
516980606ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine.Ann Oncol2006https://conductscience.org/library/papers/16980606PubMed
612570657Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation.Curr Cancer Drug Targets2003https://conductscience.org/library/papers/12570657PubMed
77563202Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833.J Natl Cancer Inst1995https://conductscience.org/library/papers/7563202PubMed
8356975Cell kinetics and chemotherapy: a critical review.Cancer Treat Rep1978https://conductscience.org/library/papers/356975PubMed
911498354Tumor cell resistance to DNA topoisomerase II inhibitors: new developments.Drug Resist Updat1999https://conductscience.org/library/papers/11498354PubMed
1011261316An explicit representation of the Luria-Delbrück distribution.J Math Biol2001https://conductscience.org/library/papers/11261316PubMed
1122356866Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance.Drug Resist Updat2012https://conductscience.org/library/papers/22356866PubMed
1222397650Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.N Engl J Med2012https://conductscience.org/library/papers/22397650PubMed
1317323126Pharmacogenetics/genomics of membrane transporters in cancer chemotherapy.Cancer Metastasis Rev2007https://conductscience.org/library/papers/17323126PubMed
1427924014The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible.Nucleic Acids Res2017https://conductscience.org/library/papers/27924014PubMed
1525928015FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irinotecan in colon and lung cancer models with ABCG2-induced resistance.Mol Cancer2015https://conductscience.org/library/papers/25928015PubMed
1623002210Intratumor heterogeneity: evolution through space and time.Cancer Res2012https://conductscience.org/library/papers/23002210PubMed
176197002Continuous infusion or bolus injection in cancer chemotherapy.Ann Intern Med1983https://conductscience.org/library/papers/6197002PubMed
1817234123Defeating drug resistance in cancer.Discov Med2006https://conductscience.org/library/papers/17234123PubMed
1916382445Regional activation of chromosomal arm 7q with and without gene amplification in taxane-selected human ovarian cancer cell lines.Genes Chromosomes Cancer2006https://conductscience.org/library/papers/16382445PubMed
203130070Hypoxic cells as specific drug targets for chemotherapy.Anticancer Drug Des1987https://conductscience.org/library/papers/3130070PubMed

See all 125 referencesDownload CSV of references

Cited by264

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 415 citations.

PMIDTitleJournalYearIn PapersSource
42897892Profiling Extrachromosomal Circular DNA (ecDNA) in Cancer via Next-Generation Sequencing: A New Frontier in Tumor Evolution and Therapy Resistance.Anticancer Agents Med Chem2026https://conductscience.org/library/papers/42897892PubMed
42812781Unravelling therapeutic resistance: role of cancer stem cell and microRNA in metastatic prostate cancer.Front Mol Biosci2026https://conductscience.org/library/papers/42812781PubMed
42811363Uncovering pan-cancer signatures of chemoresistance.Genome Med2026https://conductscience.org/library/papers/42811363PubMed
42803866Design, green synthesis, and anticancer evaluation of novel sulfaguanidine-based heterocycles as multi-target inhibitors of the VEGFR-2/PI3K/AKT/mTOR pathway.Mol Cell Biochem2026https://conductscience.org/library/papers/42803866PubMed
42757169Targeting cancer hallmarks with microbiome-derived bacteriocins and postbiotics: molecular mechanisms and translational opportunities in oncology.Front Oncol2026https://conductscience.org/library/papers/42757169PubMed
42684565Integrated roles of miR-125b, miR-375, and miR-451 in breast cancer chemoresistance: mechanistic insights and translational implications.Mol Biol Rep2026https://conductscience.org/library/papers/42684565PubMed
42669594Natural Product Toosendanin Suppresses the Malignant Development of Skin Melanoma by Targeting BNC2 for Degradation.Adv Sci (Weinh)2026https://conductscience.org/library/papers/42669594PubMed
42321357Allicin-loaded soluplus polymeric micelles differentially modulate doxorubicin response in adenocarcinoma and myocardial cell models.Sci Rep2026https://conductscience.org/library/papers/42321357PubMed
42312160Unveiling the Role of Glutathione S‑transferase Protein in Breast Cancer Drug Resistance: Insights into the Signaling Pathways and Therapeutic Implications.ACS Pharmacol Transl Sci2026https://conductscience.org/library/papers/42312160PubMed
42277467Innovative strategies to overcome cancer drug resistance: from nanodelivery systems to targeted therapeutics.Discov Oncol2026https://conductscience.org/library/papers/42277467PubMed
42215431Ferroptosis vulnerability of enzalutamide resistant prostate cancer conferred by ACSL4 overexpression and GPX4 antagonism.Cell Death Dis2026https://conductscience.org/library/papers/42215431PubMed
42212337Neutrophil Extracellular Traps in Pancreatic Ductal Adenocarcinoma: A Vicious Cycle in the Tumor Microenvironment and Targeted Interventions.Int J Biol Sci2026https://conductscience.org/library/papers/42212337PubMed
42198418A Fivefold Maximum Drug-Likeness Strategy for Prioritizing Antibacterial Candidates Against Escherichia coli.Pharmaceuticals (Basel)2026https://conductscience.org/library/papers/42198418PubMed
42196226Two Worlds, One Battle: How Bacteria and Malignancies Converge on Drug Resistance.Int J Mol Sci2026https://conductscience.org/library/papers/42196226PubMed
42036657Integrated transcriptomic and proteomic analysis of cancer-suppressive Mesocestoides corti larvae.Parasit Vectors2026https://conductscience.org/library/papers/42036657PubMed
41831174Genomic profiling enables personalized strategies to overcome drug resistance in multiple myeloma.Discov Oncol2026https://conductscience.org/library/papers/41831174PubMed
41822854Therapeutic Potential of Silver Nanoparticles in Hepatocellular Carcinoma: From Pathogenesis to Clinical Perspectives.Int J Nanomedicine2026https://conductscience.org/library/papers/41822854PubMed
41793674Metabolite Profiling and Network Pharmacology of Persimmon Vinegar (Diospyros kaki) Compounds, with in silico Validation for Non-Small Cell Lung Cancer Therapy.Asian Pac J Cancer Prev2026https://conductscience.org/library/papers/41793674PubMed
41754887Navigating the Challenges of Metallopharmaceutical Agents: Strategies and Predictive Modeling for Skin Cancer Therapy.Pharmaceutics2026https://conductscience.org/library/papers/41754887PubMed
41751863Posidonia oceanica (L.) Delile in Focus: In Vitro and In Vivo Evidence for Biomedical Potential.Int J Mol Sci2026https://conductscience.org/library/papers/41751863PubMed

See all 264 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/29799080

GET https://conductscience.org/api/papers/v1/29799080/references?page=2